ORCID as entered in ROS
https://orcid.org/0000-0002-4257-7620
Select Publications
Conference Papers
, 2020, 'Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop', in American Journal of Kidney Diseases, pp. 109 - 120, http://dx.doi.org/10.1053/j.ajkd.2020.01.022
, 2020, 'EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 152 - 152, presented at
, 2020, 'REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 183 - 183, presented at
, 2020, 'Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency', in American Journal of Kidney Diseases, pp. 84 - 104, http://dx.doi.org/10.1053/j.ajkd.2019.06.009
, 2019, 'Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial', in DIABETES-METABOLISM RESEARCH AND REVIEWS, WILEY, PEOPLES R CHINA, Xiamen, presented at
, 2019, 'Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, presented at
, 2019, 'First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, FRANCE, Paris, pp. 3877 - 3877, presented at
, 2018, 'Effects of the DPP-4 Inhibitor Linagliptin on Heart Failure Outcomes in Patients With Type 2 Diabetes and Cardio-Renal Disease in CARMELINA', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, pp. E771 - E772, presented at
, 2018, 'Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease', in DIABETOLOGIA, SPRINGER, GERMANY, Berlin, pp. S39 - S39, presented at
, 2018, 'Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes-The ADVANCE Trial', in DIABETES, AMER DIABETES ASSOC, FL, Orlando, presented at
, 2017, 'Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, CA, Anaheim, pp. E454 - E455, presented at
, 2017, 'CARMELINA® trial baseline characteristics: a cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S357 - S357, presented at
, 2017, 'CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk', in DIABETES, AMER DIABETES ASSOC, CA, San Diego, pp. A344 - A344, presented at
, 2017, 'EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, pp. 12 - 12
, 2017, 'EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS
, 2016, 'Canagliflozin slows progression of renal function decline independent of glycaemic effects', in DIABETOLOGIA, SPRINGER, GERMANY, Munich, pp. S28 - S28, presented at
, 2016, 'Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes: the MARLINA-T2D™ trial', in DIABETOLOGIA, SPRINGER, GERMANY, Munich, pp. S360 - S360, presented at
, 2016, 'Haemodynamic effects of combination therapy with the DPP-4 inhibitor linagliptin and renin-angiotensin system inhibitors in patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, GERMANY, Munich, pp. S366 - S367, presented at
, 2016, 'Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference', in Kidney International, Paris, France, pp. 297 - 305, presented at
, 2016, 'IS IMMUNOSUPPRESSIVE THERAPY BENEFICIAL FOR IDIOPATHIC MEMBRANOUS NEPHROPATHY: A SYSTEMATIC REVIEW AND TRIAL SEQUENTIAL ANALYSIS OF PUBLISHED TRIALS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 112 - 112, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'TRENDS IN HAEMOGLOBIN CONCENTRATION AND ERYTHROPOIESIS STIMULATING AGENT (ESA) USE IN THE AUSTRALIAN DIALYSIS POPULATION', in NEPHROLOGY, WILEY-BLACKWELL, pp. 119 - 120, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600171&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'TRENDS IN THE RELATIVE SURVIVAL OF MIDDLE AGED AND OLDER PEOPLE ON DIALYSIS IN AUSTRALIA', in NEPHROLOGY, WILEY-BLACKWELL, pp. 98 - 98, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'Canagliflozin (CANA) Slows Progression of Renal Function Decline Independent of Glycemic Effects', in DIABETES, AMER DIABETES ASSOC, LA, New Orleans, pp. A18 - A18, presented at
, 2016, 'EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, AUSTRIA, Vienna, pp. 413 - 413, presented at
, 2016, 'EFFECTS OF LINAGLIPTIN ON GLYCAEMIC CONTROL AND ALBUMINURIA IN TYPE 2 DIABETES - THE MARLINA-T2D™ TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, pp. 60 - 60
, 2015, 'EFFECTS OF THE MEDITERRANEAN DIET ON CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS', in Journal of the American College of Cardiology, Elsevier, pp. a1448, http://dx.doi.org/10.1016/s0735-1097(15)61448-6
, 2015, 'THE REGISTRATION OF RANDOMISED TRIALS IN NEPHROLOGY: AN INTERNATIONAL REVIEW', in NEPHROLOGY, WILEY-BLACKWELL, pp. 28 - 29
, 2014, 'DIETARY SODIUM REDUCTION REDUCED ALBUMINURIA IN 1,903 RURAL CHINESE: A CLUSTER RANDOMISED TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339715700044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'RESEARCH PRIORITIES IN CHRONIC KIDNEY DISEASE: A PRIORITY SETTING PARTNERSHIP', in NEPHROLOGY, WILEY-BLACKWELL, pp. 52 - 52, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339715700132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'Long-term Efficacy and Safety of Linagliptin in Type 2 Diabetes Patients with Moderate to Severe Renal Disease', in DIABETES, AMER DIABETES ASSOC, pp. A264 - A264, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359481601352&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Canagliflozin is effective and generally well tolerated in subjects with type 2 diabetes mellitus and Stage 3 chronic kidney disease', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, pp. S382 - S382, presented at
, 2013, 'Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, pp. S364 - S364, presented at
, 2013, 'THE IMPACT OF HAEMODIAFILTRATION, HAEMOFILTRATION AND HAEMODIALYSIS ON CLINICAL OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323453000052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'High sensitivity cardiac troponin T and N-terminal pro-BNP predict cardiovascular events and death in patients with type 2 diabetes mellitus', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, NETHERLANDS, Amsterdam, pp. 301 - 301, presented at
, 2013, 'Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy', in DIABETES, AMER DIABETES ASSOC, pp. A292 - A292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209473601437&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'ANTICOAGULANTS FOR PREVENTION OF INTRAVASCULAR CATHETERS MALFUNCTION IN PATIENTS UNDERGOING HEMODIALYSIS: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED, CONTROLLED TRIALS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 31 - 32, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307544400017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment for Diabetic Nephropathy', in DIABETES, AMER DIABETES ASSOC, pp. A243 - A243, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209842902114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy', in DIABETOLOGIA, SPRINGER, pp. S20 - S21
, 2011, 'HOW RELIABLE IS VISIT-TO-VISIT CLINIC BLOOD PRESSURE VARIABILITY?', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, Perth, pp. 498 - 498, presented at
, 2011, 'AGE AND CO-MORBIDITY, BUT NOT ESA DOSE OR HAEMOGLOBIN, ARE IMPORTANT ASSOCIATIONS WITH MORTALITY IN A PROSPECTIVELY FOLLOWED COHORT OF DIALYSIS PATIENTS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 63 - 63, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294977600152&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'CIRCULATING BONE MORPHOGENETIC PROTEIN-7 (BMP7) AND TRANSFORMING GROWTH FACTOR-beta 1 (TGF beta 1) AS POTENTIAL BIOMARKERS FOR RENAL ENDPOINTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 24 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294977600003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'OUTCOMES OF PATIENTS RECEIVING EXTENDED HOURS HAEMODIALYSIS (EHHD)', in NEPHROLOGY, WILEY-BLACKWELL, pp. 63 - 63, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294977600151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2010, 'ASPIRIN BENEFIT INCREASES AS eGFR DECLINES: RESULTS FROM A RANDOMISED CONTROLLED TRIAL IN A HYPERTENSIVE POPULATION', in NEPHROLOGY, WILEY-BLACKWELL, pp. 49 - 49, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652700087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2010, 'FACTORS ASSOCIATED WITH SURVIVAL IN ELDERLY DIALYSIS PATIENTS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 27 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652700004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2010, 'OUTCOMES ASSOCIATED WITH EXTENDED HOURS HAEMODIALYSIS (EHHD)', in NEPHROLOGY, WILEY-BLACKWELL, pp. 38 - 38, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652700044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2010, 'URAEMIC NEUROPATHY REMAINS UBIQUITIOUS: RATIONALE AND FEASIBILITY OF THE FINESSE (FILTRATION IN THE NEUROPATHY OF END STAGE KIDNEY DISEASE SYMPTOM EVOLUTION) TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, pp. 88 - 88, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652700236&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2010, 'MANAGEMENT OF CHRONIC KIDNEY DISEASE IN AUSTRALIAN GENERAL PRACTICE (THE AUSHEART STUDY)', in NEPHROLOGY, WILEY-BLACKWELL, pp. 71 - 71
, 2009, 'THE BENEFITS OF A FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, Sydney, pp. 1502 - 1502, presented at
, 2009, 'A COMPARISON OF CT GUIDED VERSUS REALTIME ULTRASOUND GUIDED PERCUTANEOUS RENAL BIOPSY', in NEPHROLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A49 - A49, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270272500182&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2009, 'EFFECT OF HOMOCYSTEINE LOWERING ON CLINICAL OUTCOMES IN PEOPLE WITH KIDNEY DISEASE: A META-ANALYSIS', in NEPHROLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A39 - A40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270272500147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Filter by type
https://orcid.org/0000-0002-4257-7620